trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['improve ', 'destiny,lung,4', 'lcsm,(-blcsm)', 'lung', 'nsclc', 'destiny,lung02', 'sclc']
#esmo22 #lcsm
updating results of destiny-lung02 trial in nsclc w/ her2-mut nsclc. after approval, an important analysis considering safety profile &amp; need to improve the understanding/management of ild
here the updating results w/ 5.4 &amp; 6.4 mg/kg: 5.9 vs 14% 
Thoracic oncologist & researcher @IEOufficiale; @myESMO Press & Media Chair; #LungCancer Molecular target-believer #LCSM